1. Home
  2. SWKH vs NKTX Comparison

SWKH vs NKTX Comparison

Compare SWKH & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • NKTX
  • Stock Information
  • Founded
  • SWKH 1996
  • NKTX 2015
  • Country
  • SWKH United States
  • NKTX United States
  • Employees
  • SWKH N/A
  • NKTX N/A
  • Industry
  • SWKH Diversified Financial Services
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWKH Finance
  • NKTX Health Care
  • Exchange
  • SWKH Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • SWKH 201.5M
  • NKTX 170.8M
  • IPO Year
  • SWKH 1999
  • NKTX 2020
  • Fundamental
  • Price
  • SWKH $16.39
  • NKTX $2.47
  • Analyst Decision
  • SWKH
  • NKTX Strong Buy
  • Analyst Count
  • SWKH 0
  • NKTX 5
  • Target Price
  • SWKH N/A
  • NKTX $15.20
  • AVG Volume (30 Days)
  • SWKH 8.6K
  • NKTX 1.5M
  • Earning Date
  • SWKH 11-14-2024
  • NKTX 11-07-2024
  • Dividend Yield
  • SWKH N/A
  • NKTX N/A
  • EPS Growth
  • SWKH N/A
  • NKTX N/A
  • EPS
  • SWKH 0.84
  • NKTX N/A
  • Revenue
  • SWKH $24,725,000.00
  • NKTX N/A
  • Revenue This Year
  • SWKH N/A
  • NKTX N/A
  • Revenue Next Year
  • SWKH $6.17
  • NKTX N/A
  • P/E Ratio
  • SWKH $19.54
  • NKTX N/A
  • Revenue Growth
  • SWKH N/A
  • NKTX N/A
  • 52 Week Low
  • SWKH $15.14
  • NKTX $2.08
  • 52 Week High
  • SWKH $18.49
  • NKTX $16.24
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 53.54
  • NKTX 50.49
  • Support Level
  • SWKH $16.25
  • NKTX $2.19
  • Resistance Level
  • SWKH $16.64
  • NKTX $2.70
  • Average True Range (ATR)
  • SWKH 0.35
  • NKTX 0.15
  • MACD
  • SWKH 0.05
  • NKTX 0.03
  • Stochastic Oscillator
  • SWKH 78.07
  • NKTX 54.90

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About NKTX Nkarta Inc.

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Share on Social Networks: